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Figure 1. CD4+ T Cells ‘‘Help’’ the Formation of Lung-Resident CD8+ Trm Cells
CD4+ T cells secrete IFN-g, which conditions the tissue microenvironment and directs the localization of
CD8+ T cells to the airway epithelia where they are subjected to Trm-promoting cytokines such as TGF-b
(left). Helped CD8+ T cells express high amounts of CD103, CD69, CXCR3, and low levels of T-bet. In
the absence of CD4+ T cell help, CD8+ T cells do not efficiently enter the airway epithelia. Unhelped CD8+
T cells show impaired expression of CD103, CXCR3, and CD69 and express high amounts of T-bet (right).
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Previewscomponents within this pathway, such as
the cytokine TGF-b and the transcription
factor T-bet, are known to have a broad
impact on T cell maturation and so might
have other effects on Trm cell formation
or survival. Nonetheless, the study by
Laidlaw and colleagues clearly highlights
that T-bet downregulation affects Trm
cell development in the lung and it will be
interesting to determine whether this is
also the case for Trm cells in other tissues.
To underscore the importance of CD4+
T cell help in Trm cell formation, Laidlaw
et al. (2014) show that unhelped CD8+
T cells were also impaired in their ability
to mediate protection against hetero-
subtypic influenza virus infection. In the
absence of CD4+ T cells, mice exhibited
both a defect in CD8+ Trm cells in thelung and decreased CD8+ T cell recruit-
ment from the blood. This compromised
recruitment could be ascribed to the
underlying defect in lung Trm cells,
which are otherwise capable of recruit-
ing cells from the circulation, much like
what was shown for Trm cells in the
female reproductive tract (Schenkel et al.,
2013). Regardless, the data indicate a
role for both resident and circulating
CD8+ T cells in mediating optimal antiviral
protection, although the relative con-
tributions of the respective subsets to pro-
tective immunity remain to be determined.
Altogether, Laidlaw and colleagues
offer mechanistic insight into Trm cell
development, which represents an essen-
tial step toward enhancing the generation
of these cells for therapeutic purposes.Immunity 41The study emphasizes the key role of
tissue microenvironment in promoting
Trm cell development, and it is likely that
location-specific cues regulate many
other properties of Trm cells. Future in-
vestigations will be vital to establish other
factors that drive this cell lineage.
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Because of its lethality, the Ebola virus often appears to be an invincible adversary. InNature, Qiu et al. (2014)
recently described the complete protection of nonhuman primates from deadly Ebola virus disease, even
when treatment was begun as late as 5 days after infection.By far the most widespread and deadly
Ebola virus emergence on record, the
2014 outbreak in West Africa continuesto expand at an exponential rate. Recent
projections suggest that many tens of
thousands of people are at risk of con-tracting this deadly disease. The grim cir-
cumstances surrounding the ongoing
epidemic highlight the lack of approved, October 16, 2014 ª2014 Elsevier Inc. 515
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Figure 1. Development of the Protective Monoclonal-Antibody
Therapy ZMapp
Two three-mAb cocktails known as MB-003 and cZMab, for which there is
prior evidence of efficacy in nonhuman primatemodels of Ebola virus infection,
were the starting point for ZMapp. Testing the efficacy on individual compo-
nents of MB-003 in guinea pigs and nonhuman primates led to the inclusion
of C13C6 in subsequent cocktails. C13C6 was then combined with pairs of
mAbs from cZMab. The combination called ZMapp1 was most effective in
nonhuman primate studies and is now called ZMapp. ZMapp protected
Ebola-virus-infected nonhuman primates, even when administered 5 days
after infection.
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Previewsvaccines and treatments
available to treat these infec-
tions. A lingering question un-
derlying the development of
therapeutics for Ebola virus
disease (EVD) has been
whether there is a window of
opportunity in which to treat
patients who present with
symptomatic disease and
how long such a window
might last. A recent study by
Qui and colleagues used
nonhuman primates, the
most rigorous animal model,
and demonstrates that a
monoclonal antibody (mAb)
cocktail called ZMapp can
be protective, even when
administered as late as
5 days after infection, a point
at which the animals are
symptomatic and viremic
(Qiu et al., 2014). The achieve-
ment of effective protection at
this late time suggests that
there exists a treatment that
might be able to help infectedpatients. It also reassures investigators
pursuing other therapeutic approaches
that Ebola virus is not the invincible oppo-
nent it has often seemed to be.
Ebola virus is an enveloped virus with
a nonsegmented, negative-sense RNA
genome of nearly 19,000 bases. The
genome has seven genes that produce
eight major translation products. Replica-
tion takes place in the host cell cytoplasm,
and all viral RNA-synthesis reactions
require four viral proteins known as nucle-
oprotein (NP), VP35, VP30, and the large
(L) protein, the enzymatic subunit of the
polymerase complex. Viral attachment
and entry is mediated by the membrane-
bound glycoprotein (GP), whereas as-
sembly and egress is directed by the viral
matrix protein, VP40. A secreted glyco-
protein (sGP) that is not incorporated
into viral particles is also produced during
infection and might function to modulate
host antibody responses to the virus.
As the only viral surface protein and the
mediator of viral attachment and entry,
GP has long been of interest as a target
of vaccines and other therapeutics, and
it can be targeted by antibodies. Panels
of monoclonal antibodies that can
neutralize Ebola virus infection in vitro
have been described, and some are pro-516 Immunity 41, October 16, 2014 ª2014 Eltective in mouse models (Wilson et al.,
2000). Interestingly, many such anti-
bodies exhibit in vitro neutralizing activity
only in the presence of complement (Wil-
son et al., 2000). GP also appears to elicit
an abundance of nonneutralizing anti-
bodies, some of which recognize the GP
mucin domain (Martinez et al., 2011).
This heavily glycosylated domain might
shield the functionally critical regions of
GP from the humoral immune response
(Lee et al., 2008).
Despite being obvious candidates
for therapeutics, antibody-based ap-
proaches have not, until recently, been
successfully developed against filovi-
ruses. Three animal models are typically
used in the testing and development
of vaccines and therapeutics for these
viruses (Bente et al., 2009). Mice and
guinea pigs are used as initial evaluation
systems, but filoviruses that can cause
lethal disease in human and nonhuman
primates do not necessarily cause lethal
disease in immunocompetent versions
of these small-animal models. One can
overcome thisbarrier by serially passaging
the virus in the animal, thereby selecting
for genetic variants with increased viru-
lence. Individual mAbs that protect mice
and guinea pigs from being killed by filovi-sevier Inc.ruses have been identified.
However, the same mAbs
have often failed as therapeu-
tics when tested in macaques
against wild-type viruses, the
gold-standard model for filo-
virus pathogenesis. There is
promise for these therapeu-
tics, however, in that more re-
cent mAb-based approaches
have achieved success in
nonhuman primate models
when cocktails of mAbs were
tested.
Two such cocktails, MB-
003 and ZMAb, each a com-
bination of three mAbs, have
been shown to provide pro-
tection in nonhuman primate
studies (Pettitt et al., 2013;
Qiu et al., 2013). What distin-
guished these mAb cocktails
from other therapeutic ap-
proaches was that each of
the mAbs exhibited some de-
gree of efficacy when given
more than one day after infec-
tion. Specifically, MB-003protected a subset of animals from death
when it was administered at a time point
after onset of symptoms. When ZMAb,
at 3 days after infection, was administered
in combination with an adenovirus vector
that expresses interferon-a (IFN-a), sub-
stantial protection from lethality was
achieved. Building on this, the two groups
of investigators joined forces and devised
a strategy to combine the best of the two
cocktails. First, the individual mAbs from
MB-003 were tested in guinea pigs and
nonhuman primates, and c13C6 was
clearly the most effective component.
C13C6 was then combined with two
ZMab components at a time. By testing
in guinea pigs and then nonhuman pri-
mates, the researchers found that the
best combination comprised three hu-
man-mouse chimeric mAbs known as
c13C6, c2G4, and c4G7. This combina-
tion is now called ZMapp by MappBio
Pharmaceuticals. Most impressively,
ZMapp was fully protective when daily
treatments were initiated 3, 4, or 5 days
after infection, by far the latest time
at which a treatment has successfully pro-
tected experimentally infected macaques
from death (Figure 1).
This work is exciting because it indi-
cates that one treatment that can provide
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Previewsprotection even after disease onset. How-
ever, it should be noted that the study
was, out of necessity, comprised of a rela-
tively small number of animals that pre-
sented with a somewhat variable disease
course. Animals receiving ZMapp also
displayed significant symptoms, even
several days into the treatment. Nonethe-
less, the study is a major milestone in the
path toward developing effective treat-
ments that can be used in people. The
fact that antibody-based treatments are
now common for human use will, it is
hoped, facilitate the further development
of ZMapp. Many questions remain, how-
ever. For example, what are the mecha-
nisms by which protection is achieved?
Why is this particular cocktail effective,
and what makes it superior to the other
combinations tested? Is this particular
combination of mAbs optimal, or might
other mAbs and other combinations
prove even better? What specific epi-
topes are targeted by the components of
ZMapp, and would antibodies to other
epitopes be as effective?
One obvious limitation of antibody-
based therapeutics for viruses is that
they are generally specific for particular
antigenic types. Even when the current
situation is brought under control, future
Ebola outbreaks will continue to appear;
although the Zaire species of Ebola virus
is causing the present outbreak, deadly
outbreaks have been caused by other
Ebola virus species, including Sudan
virus and Bundibugyo virus. In addition,
the Marburg viruses, which, like Ebola vi-
ruses belong to the filovirus family, cause
severe disease, as exemplified by the
2005 Angola Marburg virus outbreak that
had a reported case fatality rate of
approximately 90%. Because the GPs of
these viruses are antigenically different,
ZMapp is unlikely to help if other filovi-
ruses like these re-emerge. Given the suc-
cess of ZMapp, however, it would make
sense to take a similar approach to these
threats and develop cocktails like ZMappfor each virus of concern. This is obviously
laborious, although understanding the
‘‘rules’’ that make ZMapp work might
facilitate the process. Another option
would be the possible development of
broadly cross-reactive antibodies that
interact with the GPs from multiple filovi-
ruses. Much progress has been made in
recent years in identifying broadly reac-
tive mAbs that can neutralize antigenically
diverse viral strains, and there has been
particular progress in generating anti-
bodies that broadly target influenza virus
andHIV-1 glycoproteins (Corti and Lanza-
vecchia, 2013). Whether this is possible
for filoviruses is uncertain, but it is encour-
aging that some mAbs that react with
multiple Ebola virus species have been
described and that two neutralizing
mAbs, one versus the Zaire species and
one versus Sudan virus, recognize struc-
turally similar regions on the respective
GPs (Dias et al., 2011; Wilson et al., 2000).
The fact that ZMapp can offer protec-
tion when given well after infection should
provide further impetus for the develop-
ment of other therapeutic modalities.
Particularly desirable would be drugs
that could be administered orally and be
given for either prophylactic or therapeu-
tic purposes. Small-molecule inhibitors
of filovirus replication would obviously
be useful in this regard. It should be
possible to develop a pan-filoviral drug
by targeting critical functional features
conserved among the various filoviruses.
Progress along these lines has been
made: small molecules that protect
nonhuman primates from Marburg virus
challenge were recently described (War-
ren et al., 2014). As the ZMapp example
demonstrates, earlier efforts that came
up short were not wasted. Rather, prior
efforts that achieved limited success
and that could have been perceived as
failures served as the basis for the suc-
cess of ZMapp and will serve as the basis
for future successes. The magnitude of
the ongoing epidemics should furtherImmunity 41spur efforts at developing successful
therapies. Underlying these efforts should
be both realistic optimism that success
can be achieved and the necessary
support to advance such approaches to
human use.
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